-
公开(公告)号：US09790504B2
公开(公告)日：2017-10-17
申请号：US14893690
申请日：2014-05-21
IPC分类号： C12N15/113 , C07H21/02 , A61K48/00 , A61K31/506 , A61K31/519 , A61K31/713 , A61K45/06 , C12Q1/68
CPC分类号： C12N15/1137 , A61K31/506 , A61K31/519 , A61K31/713 , A61K45/06 , C12N15/113 , C12N2310/14 , C12N2320/12 , C12N2320/30 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158
摘要： Panels, compositions, and methods for treating cancer in a subject in need thereof are disclosed involving one or more genes the suppression of which renders the cancer chemosensitive and/or radiosensitive.
-
公开(公告)号：US20100221228A1
公开(公告)日：2010-09-02
申请号：US12161763
申请日：2007-01-24
CPC分类号： C12N9/1205 , A61K35/763 , A61K38/00 , C07K2319/43 , C12N15/86 , C12N2710/16632 , C12N2710/16643 , A61K2300/00
摘要： The invention provides materials and methods for the identification of cells exhibiting a cell proliferative disorder that are amenable to treatment with a herpes simplex virus that does not express an approximately wild-type level of ICP34.5. Also provided are methods of treating cell proliferative diseases, disorders or conditions, such as cancers, rheumatoid arthritis and macular degeneration, using these HSVs. Further provided are methods for preventing such cell proliferative disorders by administering the HSVs as well as methods for ameliorating a symptom associated with a cell proliferative disorder by administering such HSVs.
摘要翻译： 本发明提供用于鉴定表现出细胞增殖性病症的细胞的材料和方法，其适于用不表达近似野生型水平的ICP34.5的单纯疱疹病毒处理。 还提供了使用这些HSV来治疗细胞增殖性疾病，病症或病症如癌症，类风湿性关节炎和黄斑变性的方法。 还提供了通过施用HSV来预防这种细胞增殖性疾病的方法以及通过施用这种HSV来改善与细胞增殖性病症相关的症状的方法。
-
公开(公告)号：US20090136452A1
公开(公告)日：2009-05-28
申请号：US12065455
申请日：2006-08-30
申请人： Guoying Zhou , Bernard Roizman
发明人： Guoying Zhou , Bernard Roizman
CPC分类号： C07K16/18 , A61K35/00 , A61K38/2086 , A61K47/642 , A61K47/6801 , A61K47/69 , A61K47/6901 , C07K14/5437 , C12N15/86 , C12N15/8695 , C12N2710/16632 , C12N2710/16643 , C12N2710/16645 , C12N2799/028 , C12N2810/50 , C12N2810/852 , C12Q1/705
摘要： The invention relates to engineered Herpes simplex virus (HSV) particles that are targeted to one or more specific binding pair members, such as receptors. Also, recombinant vectors for producing such HSV particles are provided. By reducing the affinity of HSV for its natural receptor(s) and increasing the affinity for a selected receptor, the HSV particles of the invention are useful for targeting cells that express the selected receptor, which itself may be a product of genetic engineering. The ability to selectively target cells render the HSV particles. particularly useful in selectively diagnosing, treating, and imaging cells bearing the selected binding pair member, such as a receptor. The invention also provides for polynucleotide-based therapy to cells bearing the selected binding pair member such as a receptor.
摘要翻译： 本发明涉及靶向一种或多种特异性结合对成员（例如受体）的工程化单纯疱疹病毒（HSV）颗粒。 此外，提供了用于生产这种HSV颗粒的重组载体。 通过降低HSV对其天然受体的亲合力并增加对所选受体的亲和力，本发明的HSV颗粒可用于靶向表达所选受体的细胞，其本身可能是遗传工程的产物。 选择性靶向细胞的能力使HSV颗粒。 特别可用于选择性地诊断，治疗和成像携带所选择的结合对成员例如受体的细胞。 本发明还提供了携带选定结合对成员例如受体的细胞的基于多核苷酸的治疗。
-
4.发明申请Methods and compositions for treatment and prevention of HSV-2 infections and conditions 失效用于治疗和预防HSV-2感染和病症的方法和组合物公开(公告)号：US20050112142A1
公开(公告)日：2005-05-26
申请号：US10830609
申请日：2004-04-23
申请人： Richard Spaete , George Kemble , Bernard Roizman , Mark Prichard
发明人： Richard Spaete , George Kemble , Bernard Roizman , Mark Prichard
IPC分类号： A61K39/245 , C07K14/035 , C12N7/04 , C12Q1/70 , A61K39/12 , C12N7/00
CPC分类号： C07K14/005 , A61K39/12 , A61K39/245 , A61K2039/5254 , A61K2039/541 , C12N7/00 , C12N2710/16622 , C12N2710/16634 , C12N2710/16661 , C12Q1/705
摘要： Live, attenuated, phenotypically stable HSV-2 viruses and methods of making and using the virus are provided. Live, attenuated HSV-2 viruses are constructed using recombinant techniques and can be used in a pharmaceutical composition for prophylactic treatment of HSV-2 infections and for treatment of recurrent HSV-2 related diseases and conditions.
摘要翻译： 提供活的，减毒的，表型稳定的HSV-2病毒以及制造和使用病毒的方法。 使用重组技术构建活的，减毒的HSV-2病毒，并且可以用于预防性治疗HSV-2感染和治疗复发性HSV-2相关疾病和病症的药物组合物中。
-
5.发明授权公开(公告)号：US06383738B1
公开(公告)日：2002-05-07
申请号：US09206676
申请日：1998-12-07
申请人： Renato Bruni , Bernard Roizman
发明人： Renato Bruni , Bernard Roizman
IPC分类号： A61K39245
CPC分类号： C07K14/005 , A61K38/00 , A61K48/00 , C07K2319/00 , C12N2710/16622 , C12N2710/16643
摘要： The present invention is directed to methods and compositions relating to the treatment of herpes simplex virus infections and the screening of compounds for activity that inhibit or promote viral latency. The previously identified ORF P gene product now has been shown to interact with certain eukaryotic splicing factors and, in a cell infected with a herpesvirus containing a derepressed ORF P gene, ORF P can limit the splicing of at least two viral products. Given this function, it now is possible to screen for inhibitors and inducers of ORF P and, further, provide methods for maintaining and preventing viral latency.
摘要翻译： 本发明涉及涉及治疗单纯疱疹病毒感染和筛选化合物以抑制或促进病毒潜伏期的活性的方法和组合物。 现在已经显示先前鉴定的ORF P基因产物与某些真核剪接因子相互作用，并且在含有去抑制ORF P基因的疱疹病毒感染的细胞中，ORF P可以限制至少两种病毒产物的剪接。 鉴于此功能，现在可以筛选ORF P的抑制剂和诱导剂，并进一步提供维持和预防病毒潜伏期的方法。
-
公开(公告)号：US5599691A
公开(公告)日：1997-02-04
申请号：US419831
申请日：1995-04-11
申请人： Bernard Roizman
发明人： Bernard Roizman
IPC分类号： A61K39/00 , A61K39/29 , A61P31/12 , A61P31/22 , C07H21/04 , C07K14/005 , C07K14/02 , C07K14/035 , C07K14/10 , C07K14/18 , C07K14/195 , C12N7/00 , C12N15/00 , C12N15/09 , C12N15/36 , C12N15/38 , C12N15/86 , C12N15/869 , C12P19/34 , C12P21/00 , C12P21/02 , C12R1/19 , C12R1/91 , C12R1/92
CPC分类号： C07K14/005 , C12N15/86 , A61K39/00 , C12N2710/16622 , C12N2710/16643 , C12N2730/10122
摘要： A foreign gene is inserted into a viral genome under the control of promoter-regulatory regions of the genome, thus providing a vector for the expression of the foreign gene. DNA constructs, plasmid vectors containing the constructs useful for expression of the foreign gene, recombinant viruses produced with the vector, and associated methods are disclosed.
摘要翻译： 外源基因在基因组的启动子调控区的控制下插入到病毒基因组中，从而提供外源基因表达的载体。 公开了DNA构建体，含有用于表达外源基因的构建体的质粒载体，用该载体产生的重组病毒和相关方法。
-
公开(公告)号：US5478727A
公开(公告)日：1995-12-26
申请号：US832855
申请日：1992-02-07
申请人： Bernard Roizman , Fenyong Liu
发明人： Bernard Roizman , Fenyong Liu
IPC分类号： A61K38/00 , C07K14/035 , C07K16/08 , C12N9/50 , C12N15/113 , C12N15/869 , C12Q1/70 , C12N15/38 , C12Q1/00 , C12Q1/37
CPC分类号： C12N15/1133 , C07K14/005 , C07K16/085 , C12N15/86 , C12N9/503 , C12Q1/705 , A61K38/00 , C12N2710/16622 , C12N2710/16643 , Y10S435/815
摘要： The present invention relates to the identification and purification of a herpes protease and a nucleic acid segment coding for two proteins. The first protein is the herpes protease which is able to cleave itself and also cleave the second protein. This protease is required for the assembly of the herpes virus capsid, therefore is essential for replication. The second protein has previously been designated as the family of proteins in viral infected cells, ICP35. The protease and its substrates are encoded by overlapping nucleic acid segments. This invention also relates to a promoter sequence for the second protein. Methods are presented of producing a viral protease, screening a protease inhibitor which may be used in a drug designed for the treatment of herpes disease, methods for treating herpes and other viral infections wherein the virus employs a protease substantially similar to the herpes protease, for capsid production. Methods for detecting herpes infections and other viral infections are also disclosed.
-
公开(公告)号：US20110274661A1
公开(公告)日：2011-11-10
申请号：US13058780
申请日：2009-08-07
CPC分类号： C07K14/005 , A61K35/763 , A61K48/0058 , C12N7/00 , C12N9/1205 , C12N15/85 , C12N15/86 , C12N2710/16622 , C12N2710/16632 , C12N2710/16643 , C12N2710/16661 , C12N2710/16662 , C12N2830/002 , C12N2830/60
摘要： The disclosure provides materials and methods for the treatment of cells exhibiting a cell proliferative disorder with a herpes simplex virus having a deficiency in the expression of active ICP34.5 and comprising an expression control element effective in modulating at least one component of the MEK pathway to ensure that infected cells are MEK+. Cell proliferative diseases, disorders or conditions, such as cancers, rheumatoid arthritis and macular degeneration, are amenable to treatment using these HSVs. Further provided are methods for preventing such cell proliferative disorders by administering the HSVs as well as methods for ameliorating a symptom associated with a cell proliferative disorder by administering such HSVs.
摘要翻译： 本公开提供用于治疗具有细胞增殖性病症的细胞的材料和方法，所述单纯疱疹病毒具有活性ICP34.5的表达缺陷，并且包含有效调节至少一种MEK途径成分的表达控制元件， 确保受感染的细胞是MEK +。 细胞增殖性疾病，疾病或病症，如癌症，类风湿关节炎和黄斑变性，适用于使用这些HSV的治疗。 还提供了通过施用HSV来预防这种细胞增殖性疾病的方法以及通过施用这种HSV来改善与细胞增殖性病症相关的症状的方法。
-
公开(公告)号：US20090011439A1
公开(公告)日：2009-01-08
申请号：US12087964
申请日：2007-01-19
IPC分类号： G01N33/574
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , G01N33/57407 , G01N33/57484 , G01N2800/52
摘要： Disclosed is a set of genes differentially expressed in chemotherapy and radiation resistant tumors useful in predicting response to therapy and assessing risk of local-regional failure, survival and metastasis in cancer patients. Also disclosed are methods for characterizing tumors according to gene expression and kits for use in the methods of the invention.
摘要翻译： 公开了一组在化学疗法和耐辐射肿瘤中差异表达的基因，可用于预测治疗反应和评估癌症患者局部局部衰竭，存活和转移的风险。 还公开了根据基因表达表征肿瘤的方法和用于本发明方法的试剂盒。
-
公开(公告)号：US20060068391A1
公开(公告)日：2006-03-30
申请号：US10530774
申请日：2003-10-06
申请人： Bernard Roizman , Gouying Zhou , Guo Ye
发明人： Bernard Roizman , Gouying Zhou , Guo Ye
CPC分类号： C12N15/86 , A61K47/642 , A61K47/6901 , C07K14/005 , C07K2319/20 , C12N2710/16622 , C12N2710/16643 , C12N2810/50 , C12N2810/852 , C12N2810/859
摘要： The invention relates to engineered Herpes simplex virus (HSV) particles that are targeted to one or more specific receptors. Also, recombinant vectors for producing such HSV particles. By reducing the affinity of HSV for its natural receptor(s) and increasing the affinity for a selected receptor, the HSV particles of the invention may be used for targeting cells that express the selected receptor. The ability to selectively target cells renders the HSV particles particularly useful in selectively killing the selected receptor-bearing cells (such as tumor cells), imaging cells bearing the selected receptor, and providing gene replacement therapy to cells bearing the selected receptor.
-
-
-
-
-
-
-
-
-
搜索结果
50 条记录 (耗时 0.024 秒)
